GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Rallybio Corporation
Rallybio is a biotech company focused on developing drugs for rare diseases. Its stock price reflects the progress of its clinical programs. Its stock price is volatile and driven by news about research, partnerships, and regulatory decisions.
Share prices of companies in the market segment - Pharma other
Rallybio is a biopharmaceutical company focused on developing treatments for rare and severe diseases affecting fetuses and newborns. We classify it as "Other Pharma." The chart below shows how investors value companies in the perinatal field.
Broad Market Index - GURU.Markets
Rallybio is a biopharmaceutical company focused on developing treatments for rare and serious diseases. It is a component of the GURU.Markets index, and the chart below shows how its stock compares to the market, reflecting investor expectations.
Change in the price of a company, segment, and market as a whole per day
RLYB - Daily change in the company's share price Rallybio Corporation
For Rallybio Corporation, which develops drugs for rare diseases, daily price changes are a measure of enormous volatility. This metric reflects extreme sensitivity to clinical trial data and is key to risk assessment.
Daily change in the price of a set of shares in a market segment - Pharma other
Rallybio Corporation is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with RLYB, which focuses on rare diseases, helps us assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Rallybio is a biotech company specializing in treating rare diseases. Its shares move in sync with news about clinical trials. This high, event-driven volatility feeds into the overall market flow, shaping its daily pattern.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Rallybio Corporation
Rallybio Corporation's year-over-year performance is a story of rare disease drug development. Its 12-month market capitalization is entirely dependent on progress in clinical trials. Success of its lead candidate for preventing a rare fetal blood disorder could be a real breakthrough in neonatology.
Annual dynamics of market capitalization of the market segment - Pharma other
Rallybio Corporation is a clinical-stage biotech company focused on developing drugs for rare diseases. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Rallybio is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Rallybio Corporation
Rallybio is a clinical-stage biopharmaceutical company focused on rare diseases. Its monthly performance is entirely dependent on the results of its clinical trials. Data from its flagship programs are binary events, causing sharp fluctuations.
Monthly dynamics of market capitalization of the market segment - Pharma other
This chart reflects the dynamics of the volatile biotech sector. For Rallybio, a clinical-stage company, it's the backdrop. Its movements show how successes and failures in clinical trials, as well as M&A activity, have influenced investor sentiment.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Rallybio is a clinical-stage biopharmaceutical company focused on developing drugs for rare diseases. Its value depends almost entirely on the results of clinical trials. The overall market has little impact on Rallybio; its shares are driven by scientific news, which can cause explosive gains or losses on any given day.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Rallybio Corporation
Rallybio, a biotech focused on developing drugs for rare diseases, is extremely volatile. Its weekly stock price is a direct response to clinical trial data, regulatory decisions, and partnership news, as every step of development is critical to its valuation.
Weekly dynamics of market capitalization of the market segment - Pharma other
Rallybio operates in the volatile biopharmaceutical sector, where investor sentiment often influences all players. M&A news or general regulatory changes can lift or derail the entire sector. The chart will show whether RLYB is moving with the industry or whether its successes in treating rare diseases are creating its own story.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Rallybio, as a biotech company, often ignores broader market trends. Its fate depends not on GDP or inflation, but on the results of clinical trials. The chart below clearly demonstrates how RLYB shares can live their own life, separate from the broader market.
Market capitalization of the company, segment and market as a whole
RLYB - Market capitalization of the company Rallybio Corporation
Rallybio's market capitalization dynamics tell a focused story about preventing rare diseases in fetuses and newborns. This biotech company's chart reflects investor expectations for its drug portfolio. Its movements reflect the market's assessment of its scientific approach and potential to create an entirely new market.
RLYB - Share of the company's market capitalization Rallybio Corporation within the market segment - Pharma other
Rallybio Corporation is a biopharmaceutical company focused on developing drugs for the treatment of serious and rare diseases. Its market share is based on its pipeline of candidates. The chart shows how the market views its scientific approach and ability to bring drugs to market for patients with unmet needs.
Market capitalization of the market segment - Pharma other
Rallybio is a biotech company focused on developing drugs to treat rare diseases. The chart below shows the market capitalization of the pharmaceutical sector. This is the valuation of a complex business where a scientific breakthrough can radically change the lives of patients with rare diagnoses.
Market capitalization of all companies included in a broad market index - GURU.Markets
Rallybio is a biopharmaceutical company developing drugs to treat rare and serious diseases. Its market capitalization reflects the potential of its scientific research. The chart below shows the economic weight of companies solving orphan diseases.
Book value capitalization of the company, segment and market as a whole
RLYB - Book value capitalization of the company Rallybio Corporation
Rallybio's book value represents capital invested in the treatment of rare diseases. Its foundation consists of the intellectual property in its pipeline of drugs aimed at preventing severe diseases in fetuses and newborns, and the funds for their clinical trials. The chart below shows how the company is building its scientific and financial foundation.
RLYB - Share of the company's book capitalization Rallybio Corporation within the market segment - Pharma other
Rallybio, a biopharmaceutical company, is focused on rare disease R&D. Its laboratories are its primary physical asset. The S_BCap_Seg graph shows its small share of physical infrastructure, typical for a company in the clinical development stage.
Market segment balance sheet capitalization - Pharma other
Rallybio is a clinical-stage biotech focused on rare diseases. Its value is derived almost entirely from the intellectual property of its drugs in development. A book value chart will demonstrate how intangible its business is while awaiting breakthrough results.
Book value of all companies included in the broad market index - GURU.Markets
Rallybio's book value represents capital invested in rare hematological diseases. The company's assets consist of development rights to several drugs and the financial resources to advance them through clinical trials. The chart shows the size of its asset base focused on protecting fetuses and newborns from platelet destruction.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Rallybio Corporation
Rallybio is a biopharmaceutical company focused on rare diseases. Its book value is primarily cash. Its market capitalization is the net valuation of its pipeline of investigational drugs and their potential to transform the lives of patients with severe and rare diseases.
Market to book capitalization ratio in a market segment - Pharma other
Rallybio is a biotech company focused on treating rare diseases. Its value depends almost entirely on the success of its clinical programs. The chart shows how market expectations for its drug candidates compare to its book value, which is primarily comprised of cash.
Market to book capitalization ratio for the market as a whole
Rallybio is a biopharmaceutical company focused on treating rare diseases. Its value is almost entirely determined by the potential of its research portfolio. The market is pricing in the hope of developing breakthrough drugs. The chart clearly demonstrates the gap between market capitalization and book value, which is typical for biotech.
Debts of the company, segment and market as a whole
RLYB - Company debts Rallybio Corporation
Rallybio, a biotech focused on rare diseases, uses debt to finance its development pipeline. This chart shows the capital raised to advance several drug candidates through the preclinical and clinical stages. This is a risk diversification strategy in the high-risk biotech industry.
Market segment debts - Pharma other
Rallybio is a clinical-stage biotech company specializing in developing drugs for rare diseases. It has no products on the market, and its survival depends entirely on its ability to raise capital to fund expensive research. This chart shows its cash position and capital burn rate.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Rallybio Corporation
Rallybio is a biopharmaceutical company specializing in rare diseases. This chart shows its leverage ratio. For a company targeting niche markets with long development cycles, debt financing is extremely risky. Its level reflects management's confidence in the success of its clinical trials.
Market segment debt to market segment book capitalization - Pharma other
Rallybio Corporation is a biotech company focused on rare diseases. This chart for the biotech sector illustrates investors' appetite for risk and funding expensive research. It helps us understand how the company's financial position is typical for an industry where the stakes and potential rewards are extremely high.
Debt to book value of all companies in the market
Rallybio is a biotech company specializing in developing drugs for rare diseases. Financing is a key factor in this field's success. The chart showing the overall debt-to-book value ratio of the market reflects investors' risk appetite. This determines how easily Rallybio can raise funds for its expensive research.
P/E of the company, segment and market as a whole
P/E - Rallybio Corporation
Rallybio is a biotech company specializing in rare diseases. This chart reflects its strategy for acquiring and developing promising drug candidates. Its value reflects how investors view its scientific expertise and the potential of its portfolio, where the success of even a single rare disease drug can generate enormous returns.
P/E of the market segment - Pharma other
Rallybio is a biotech company. This chart shows the average P/E for the biotech sector. Comparing the company's P/E to this benchmark allows us to understand how highly the market values its rare disease drug portfolio compared to the average prospects of other biotech companies operating in the same field.
P/E of the market as a whole
Rallybio is a biopharmaceutical company specializing in developing drugs for rare diseases. Its strategy is to acquire and develop promising assets. This chart shows the mood in the biotech sector. It helps understand how successful Rallybio is in selecting and developing its candidates and how its valuation compares to other companies working in the orphan disease field.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Rallybio Corporation
Rallybio is a biotech company focused on developing drugs for rare and severe diseases. The chart reflects investor expectations for future revenue, which are entirely dependent on the success of clinical trials for its pipeline of candidates. It's a classic biotech story, where the risk and potential reward are very high.
%20P%2FE%20Rallybio%20Corporation&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Rallybio-Corporation&v=1772661074234 "Chart of the company's future (projected) P/E Rallybio Corporation")
Future (projected) P/E of the market segment - Pharma other
Rallybio is a clinical-stage company specializing in developing treatments for rare and severe fetal and neonatal diseases. This chart displays its expected future profitability, allowing us to assess how highly the market values its noble mission and scientific potential in this complex field.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-other&v=1772661074250 "Future (projected) P/E graph of the market segment - Pharma other")
Future (projected) P/E of the market as a whole
Rallybio is a clinical-stage biotech company focused on developing drugs for rare diseases. Its value is based on the expected future success of its drug candidates. It is completely unrelated to general market forecasts and depends solely on scientific data.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772661074253 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Rallybio Corporation
Rallybio Corporation is a clinical-stage biopharmaceutical company specializing in developing drugs for rare diseases. Its financial performance reflects significant investments in research and development. This chart illustrates the capital expenditures required to develop and bring to market drugs for patients with unmet medical needs.
Profit of companies in the market segment - Pharma other
Rallybio Corporation is a clinical-stage biopharmaceutical company focused on developing treatments for rare and severe fetal and neonatal diseases. This chart reflects the profitability of its segment. The company's R&D costs impact its current overall profitability, but its success could bring life-saving treatments to market and drive growth for the entire niche.
Overall market profit
Rallybio Corporation is a clinical-stage biopharmaceutical company focused on developing drugs for rare diseases. Its value and future depend solely on the success of its scientific research. This chart illustrates general economic cycles, which have little impact on the underlying logic of development and the potential of Rallybio's drug portfolio.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Rallybio Corporation
Rallybio is a clinical-stage biopharmaceutical company focused on developing treatments for rare and serious diseases. The future revenue forecast shown in this chart is long-term and depends entirely on the success of its scientific development and clinical trials. It reflects analysts' confidence in the potential of the company's pipeline.
%20profit%20of%20the%20company%20Rallybio%20Corporation&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Rallybio-Corporation&v=1772661074288 "Graph of future (projected) profit of the company Rallybio Corporation")
Future (predicted) profit of companies in the market segment - Pharma other
Rallybio Corporation is a clinical-stage biopharmaceutical company focused on developing treatments for severe and rare diseases. This chart shows profitability projections for the pharmaceutical sector. It reflects investor expectations for the company's pipeline of developments targeting unmet medical needs.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-other&v=1772661074305 "Graph of future (predicted) profits of companies in a market segment - Pharma other")
Future (predicted) profit of the market as a whole
Rallybio Corporation is a biotech company focused on rare diseases. Their operations are not tied to economic cycles, but their funding is directly related. Expectations of overall market revenue growth create a favorable environment for venture capital investments in risky but promising projects, which are crucial to Rallybio's future.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772661074307 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Rallybio Corporation
Rallybio Corporation is a biotechnology company focused on developing drugs for the treatment of rare diseases. Currently in the clinical stage, it has no sales revenue. P/S will become a key metric after commercialization, reflecting how the market will evaluate its first product and its market potential.
P/S market segment - Pharma other
Rallybio is a clinical-stage biopharmaceutical company specializing in developing treatments for rare diseases. Their approach is based on a deep understanding of the biology of these diseases. This chart reflects how investors value their scientific platform and development pipeline, placing a premium on the potential for future revenue in the orphan market.
P/S of the market as a whole
Rallybio is a biotech company specializing in developing drugs for rare diseases. The company has no commercial revenue, and its value is based on the potential of its scientific developments. This chart, showing the valuation of companies with real revenues, highlights the speculative nature of clinical-stage biotech investments.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Rallybio Corporation
Rallybio is a biotech company focused on developing treatments for rare diseases. Its valuation is based on the potential of its clinical programs. This chart reflects investor expectations for future revenue from the commercialization of its drugs, should they be successful and address unmet medical needs.
%20P%2FS%20Rallybio%20Corporation&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Rallybio-Corporation&v=1772661074369 "The graph of the company's future (projected) P/S Rallybio Corporation")
Future (projected) P/S of the market segment - Pharma other
Rallybio Corporation is a clinical-stage biopharmaceutical company focused on identifying and developing treatments for rare diseases. This chart shows how the market perceives the future commercial potential of its pipeline. It compares it to other pharmaceutical companies, reflecting investor confidence in its ability to discover and develop promising drugs.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20other&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-other&v=1772661074383 "Future (projected) P/S market segment graph - Pharma other")
Future (projected) P/S of the market as a whole
Rallybio is a biotech company specializing in developing drugs for rare diseases. Its model is to discover and develop promising scientific discoveries. This chart shows the market's aggregate revenue expectations, and RLYB exemplifies how investing in science and orphan disease treatments generates long-term value.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772661074388 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Rallybio Corporation
Rallybio Corporation is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases. Because all of its drugs are in development and not yet commercialized, the company has no sales revenue. Any revenue shown in this chart may be related to partnerships.
Sales of companies in the market segment - Pharma other
Rallybio is a biotech company focused on treating rare diseases. At this stage, its revenue, if any, may come from licensing agreements with major pharmaceutical companies. This chart allows investors to assess financial support, which is an indicator of trust in its scientific developments.
Overall market sales
Rallybio Corporation is a biotechnology company focused on developing treatments for rare diseases. Its value and prospects depend solely on clinical trial success. This market performance chart is irrelevant to Rallybio's valuation, as its mission is science and medicine.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Rallybio Corporation
Rallybio is a clinical-stage biopharmaceutical company focused on developing drugs for rare diseases. Its revenue forecast is based entirely on expectations of future clinical trial success. This chart reflects analysts' speculative assessment of the potential of its pipeline.
%20sales%20of%20the%20company%20Rallybio%20Corporation&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Rallybio-Corporation&v=1772661074447 "Schedule of future (projected) sales of the company Rallybio Corporation")
Future (projected) sales of companies in the market segment - Pharma other
Rallybio is a biopharmaceutical company specializing in developing drugs for rare diseases. This chart shows projected revenues for the entire pharmaceutical sector. For a niche company like Rallybio, general trends help assess the investment climate in the industry, which is critical for funding long-term clinical trials.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-other&v=1772661074459 "Schedule of future (projected) sales of companies in the market segment - Pharma other")
Future (projected) sales of the market as a whole
Rallybio Corporation is a biotechnology company focused on developing drugs for rare diseases. Its success depends entirely on the results of clinical trials. This graph of overall market expectations reflects the investment climate. A positive environment facilitates raising the capital needed to finance long-term and risky R&D projects.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772661074460 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Rallybio Corporation
Rallybio Corporation is a clinical-stage biopharmaceutical company specializing in developing drugs for rare diseases. This chart reflects its current focus on research. It doesn't show profit, but rather the effectiveness of managing capital invested in clinical trials, the success of which determines the company's value.
Market segment marginality - Pharma other
Rallybio Corporation is a biopharmaceutical company focused on identifying and developing treatments for rare and serious diseases. This chart shows the average profitability in the biotech sector. It gives investors an idea of the potential return on Rallybio's portfolio of drugs if they successfully complete clinical trials and enter the rare disease market.
Market marginality as a whole
Rallybio Corporation is a clinical-stage biotech company focused on rare diseases. Its value comes from the potential of its scientific developments. This average market return chart has no relevance to the biotech world, where investors evaluate the likelihood of a scientific breakthrough and the development of a new drug rather than current revenue.
Employees in the company, segment and market as a whole
Number of employees in the company Rallybio Corporation
Rallybio is a clinical-stage biopharmaceutical company focused on rare diseases. Its team consists of experienced scientists and managers who specialize in effectively advancing drugs through clinical trials. This chart shows the size of the focused team working to build a portfolio of valuable assets.
Share of the company's employees Rallybio Corporation within the market segment - Pharma other
Rallybio Corporation is a clinical-stage biopharmaceutical company focused on developing treatments for severe and rare diseases. This chart illustrates its scientific focus. It reflects the percentage of leading hematologists and researchers working on developing treatments to prevent rare blood disorders in newborns that Rallybio brings together.
Number of employees in the market segment - Pharma other
Rallybio Corporation is a biopharmaceutical company focused on developing drugs to treat serious and rare diseases. This chart shows overall employment in the pharmaceutical industry. The growing number of scientists in this field reflects increased investment in biotechnology and the search for breakthrough treatments for patients with unmet medical needs.
Number of employees in the market as a whole
Rallybio Corporation is a biotechnology company focused on developing therapies for patients with rare diseases. Pharmaceutical research is a long-term investment in science and talent. This graph shows overall employment, and growth in biotech indicates the development of an innovative economy and the creation of highly skilled jobs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Rallybio Corporation (RLYB)
Rallybio Corporation is a clinical-stage biopharmaceutical company. Its market capitalization is a bet on the future success of its drugs. This chart shows the enormous value investors place on each scientist on the team. It's a pure valuation of the intellectual capital and potential of their research portfolio.
%20of%20the%20company%20Rallybio%20Corporation%20(RLYB)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Rallybio-Corporation-RLYB&v=1772661074566 "Chart of market capitalization per employee (in thousands of dollars) of the company Rallybio Corporation (RLYB)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma other
Rallybio is a biotech company specializing in rare diseases. Its value lies in the potential of the drugs it develops. Its market capitalization per employee can be extremely high, reflecting investor expectations for blockbuster drug approvals. This is an indicator not of current performance, but of the future prospects of its research portfolio.
%20by%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-other&v=1772661074580 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma other")
Market capitalization per employee (in thousands of dollars) for the overall market
Rallybio is a biotech company specializing in developing drugs for rare diseases. The company's value is entirely dependent on the success of its R&D. This chart demonstrates the high value of each employee scientist, as their work could lead to the creation of a life-saving treatment for patients with limited treatment options.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772661074688 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Rallybio Corporation (RLYB)
Rallybio is a biotech company focused on developing drugs for rare (orphan) diseases. The company has no products on the market; its business is R&D. This graph is in negative territory and shows how much investor capital is burned for each scientist working on these complex diseases.
%20Chart%20Rallybio%20Corporation%20(RLYB)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Rallybio-Corporation-RLYB&v=1772661074730 "Company Profit Per Employee (in thousands of dollars) Chart Rallybio Corporation (RLYB)")
Profit per employee (in thousands of dollars) in the market segment - Pharma other
Rallybio is a biotech company specializing in developing treatments for rare diseases. In this niche, the value of a single successful drug can be enormous. This chart illustrates the potential of their developments. It shows how highly profitable a single innovative product created by a small team of scientists can be, a key factor for investors.
%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-other&v=1772661074756 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma other")
Profit per employee (in thousands of dollars) for the market as a whole
Rallybio Corporation is a clinical-stage biopharmaceutical company specializing in rare (orphan) diseases. Like many biotech companies, this metric reflects R&D intensity. It shows how much the company invests in research per employee to bring drugs to market for rare and serious diseases.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772661074819 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Rallybio Corporation (RLYB)
Rallybio Corporation is a clinical-stage biopharmaceutical company focused on rare diseases. This graph, showing zero revenue per employee, is typical for the industry. It illustrates a period when all resources are focused on research. Future drug success will lead to explosive growth in this metric.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Rallybio-Corporation-RLYB&v=1772661074835 "Sales chart per company employee Rallybio Corporation (RLYB)")
Sales per employee in the market segment - Pharma other
Rallybio Corporation (RLYB) is a biopharmaceutical company specializing in developing treatments for rare diseases, particularly in hematology and immunology. This chart shows the average revenue per employee in the pharmaceutical segment. For Rallybio, which is in the R&D stage, comparing it to this benchmark (zero) highlights their focus on science rather than current sales.
Sales per employee for the market as a whole
Rallybio (RLYB) is a clinical-stage biotech company specializing in rare diseases. Like other biotechs without a product (AKTX, LIXT), the company has no revenue. This metric is zero. Investors are focused entirely on clinical trial data, which is the sole driver of the company's value at this stage.
Short shares by company, segment and market as a whole
Shares shorted by company Rallybio Corporation (RLYB)
Rallybio Corporation is a clinical-stage biotech company focused on treating rare diseases, specifically protecting the fetus from maternal immune attack. This chart shows high skepticism. The bears are making a classic bet that their complex therapy will fail in clinical trials, which is par for the course in this sector.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Rallybio-Corporation-RLYB&v=1772661075020 "Short Shares Chart for the Company Rallybio Corporation (RLYB)")
Shares shorted by market segment - Pharma other
Rallybio (RLYB) is a biotech focused on a highly complex niche: treating rare diseases in fetuses and newborns. This chart shows pessimism across the sector. The growing short position across the industry is a risk-off signal. Investors are avoiding risky biotechs, especially those working in ethically and scientifically challenging areas. They doubt the success of clinical trials in such a vulnerable patient group.
Shares shorted by the overall market
Rallybio is a clinical-stage biotech focused on rare (orphan) diseases. It's a long and expensive road. This graph reflects a common fear. When investors are pessimistic, they're reluctant to fund years of R&D. They see RLYB burning through capital and fear the company won't survive to see the drug approved given the high cost of funding.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Rallybio Corporation (RLYB)
Rallybio (RLYB) is a biotech company specializing in rare diseases, specifically protecting fetuses and newborns from maternal immune responses. This is an important niche. This indicator measures the strength of price movements. It helps identify when the stock is "overheated" (above 70) due to data expectations or "oversold" (below 30) due to delays or capital dilution.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Rallybio-Corporation-RLYB&v=1772661075116 "RSI 14 indicator chart for the company's stock Rallybio Corporation (RLYB)")
RSI 14 Market Segment - Pharma other
Rallybio (RLYB) is a biotech company specializing in rare diseases. They focus on developing drugs to prevent severe diseases in fetuses and newborns. This chart tracks overall sentiment in the Pharmaceuticals sector. It helps investors understand whether RLYB's performance reflects their niche or whether the entire biotech sector is overheated or oversold.
RSI 14 for the overall market
Rallybio (RLYB) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast RLYB (Rallybio Corporation)
Rallybio is a biotech company focused on developing treatments for rare hematological (blood-related) diseases. This chart shows the speculative average 12-month price target from analysts, which is based almost entirely on their assessment of clinical trial data.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-RLYB-Rallybio-Corporation&v=1772661075187 "A chart showing analyst consensus forecasts for the expected stock price. RLYB (Rallybio Corporation)")
The difference between the consensus estimate and the actual stock price RLYB (Rallybio Corporation)
Rallybio is a biotech company focused on developing drugs to treat rare diseases, specifically those preventing HDFN (a fetal heart disease). This chart shows how the current share price differs from the "fair" value predicted by analysts. It reflects their confidence in the company's R&D portfolio.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-RLYB-Rallybio-Corporation&v=1772661075235 "A chart showing the difference between the consensus forecast and the actual stock price. RLYB (Rallybio Corporation)")
Analyst consensus forecast for stock prices by market segment - Pharma other
Rallybio is a biotech company focused on treating rare diseases, specifically preventing a rare but dangerous fetal blood disorder. This chart shows analysts' overall expectations across the pharmaceutical sector. It reflects whether experts believe R&D in ultra-rare diseases will be commercially successful.
Analysts' consensus forecast for the overall market share price
Rallybio is a biotech company specializing in developing drugs to treat rare hematological (blood-related) diseases. This chart shows the overall market "risk appetite." For Rallybio, a high-risk clinical-stage company, overall market optimism is critical to attracting the capital needed to fund long-term research.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Rallybio Corporation
Rallybio is a clinical-stage biotech focused on rare diseases (primarily hematology and immunology). Their R&D strategy is to select winners with a high probability of success. This chart is a clear indicator of their R&D pipeline. It reflects their progress in clinical trials and the market's confidence in their low-risk (for a biotech) approach.
AKIMA Market Segment Index - Pharma other
Rallybio (RLYB) is a biopharmaceutical company specializing in rare diseases. They develop drugs to prevent severe fetal and neonatal disorders (such as FNAIT) and treat other orphan diseases. The chart shows the average index for the segment, helping investors assess how RLYB's risks in this niche compare to the average.
The AKIM Index for the overall market
Rallybio is a biotech company focused on developing drugs to treat rare and severe diseases (fetal/neonatal thrombocytopenia). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this clinical-stage research story compares to overall economic trends.
